Lapatinib Tablets 250 mg
LAPALIEVA 250 MG (Lapatinib Tablets 250 mg) is a targeted anticancer medicine used in the treatment of certain types of HER2-positive breast cancer. It contains Lapatinib, an advanced tyrosine kinase inhibitor (TKI) that works by blocking specific proteins responsible for the growth and spread of cancer cells. This targeted therapy is widely prescribed by oncologists for patients with advanced, metastatic, or treatment-resistant breast cancer.
Breast cancer remains one of the most commonly diagnosed cancers worldwide. In some patients, cancer cells produce excessive amounts of a protein known as Human Epidermal Growth Factor Receptor 2 (HER2). This protein promotes rapid cancer cell growth and increases the aggressiveness of the disease. LAPALIEVA 250 MG helps control this process by targeting HER2 and Epidermal Growth Factor Receptor (EGFR), thereby slowing cancer progression and supporting long-term disease management.
Unlike traditional chemotherapy, Lapatinib specifically targets cancer-related pathways, making it an important component of modern precision oncology treatment. It is often used in combination with other anticancer medicines to improve treatment outcomes and help patients achieve better disease control.
LAPALIEVA 250 MG is commonly prescribed for:
• HER2-positive metastatic breast cancer
• Advanced breast cancer
• Hormone receptor-positive and HER2-positive breast cancer
• Recurrent breast cancer
• Combination targeted therapy protocols
• Long-term oncology treatment programs
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, efficacy, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and cancer treatment.
Patients receiving LAPALIEVA 250 MG may require regular medical monitoring, imaging studies, liver function assessments, and cardiac evaluations throughout therapy. These assessments help doctors evaluate treatment effectiveness and identify any potential complications early.
Because of its proven effectiveness in HER2-positive breast cancer treatment, LAPALIEVA 250 MG has become an important part of modern targeted cancer therapy and personalized oncology care.
View Details
Letrozole Tablets IP 2.5 mg
LETROLIEVA 2.5 MG (Letrozole Tablets IP 2.5 mg) is a prescription medicine used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It contains Letrozole 2.5 mg, a highly effective aromatase inhibitor that helps reduce estrogen levels in the body. Since certain breast cancers depend on estrogen for growth and survival, lowering estrogen levels can help slow or stop the growth of cancer cells.
Breast cancer is one of the most common cancers affecting women worldwide. In many cases, cancer cells possess hormone receptors that respond to estrogen. LETROLIEVA 2.5 MG works by blocking the aromatase enzyme, which is responsible for producing estrogen in postmenopausal women. By reducing estrogen production, the medicine helps prevent cancer cells from receiving the hormonal stimulation they need to grow.
Letrozole is widely used as part of modern hormone therapy and targeted breast cancer treatment programs. It may be prescribed after surgery, radiation therapy, chemotherapy, or as a long-term maintenance treatment to reduce the risk of cancer recurrence.
LETROLIEVA 2.5 MG is commonly prescribed for:
• Hormone Receptor-Positive Breast Cancer
• Early-Stage Breast Cancer
• Advanced Breast Cancer
• Metastatic Breast Cancer
• Adjuvant Hormonal Therapy
• Long-Term Breast Cancer Management
• Postmenopausal Breast Cancer Treatment
In addition to its role in oncology, Letrozole may sometimes be prescribed for fertility-related conditions under specialist supervision. However, its primary use remains breast cancer treatment and management.
Manufactured under stringent pharmaceutical quality standards, LETROLIEVA 2.5 MG is designed to provide consistent therapeutic performance and reliable treatment outcomes. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hormone therapy.
Patients receiving Letrozole therapy may require regular medical monitoring, bone density assessments, cholesterol evaluations, and routine follow-up visits to ensure safe and effective treatment.
Due to its proven effectiveness in reducing breast cancer recurrence and supporting long-term disease control, LETROLIEVA 2.5 MG has become an essential medicine in modern breast cancer care.
View Details
Anastrozole Tablets 1 mg
ANALIEVA 1 MG (Anastrozole Tablets 1 mg) is a prescription hormone therapy medicine used for the treatment and management of hormone receptor-positive breast cancer in postmenopausal women. It contains Anastrozole 1 mg, a highly effective aromatase inhibitor that helps reduce estrogen production in the body. Since many breast cancers depend on estrogen to grow and spread, lowering estrogen levels can help slow cancer progression and reduce the risk of recurrence.
Breast cancer is one of the most common cancers affecting women globally. In hormone receptor-positive breast cancer, cancer cells use estrogen as a growth signal. ANALIEVA 1 MG works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogen in postmenopausal women. By significantly reducing estrogen levels, the medicine helps prevent cancer cells from receiving the hormonal stimulation they need to survive and multiply.
Anastrozole has become an important part of modern breast cancer treatment protocols and is widely recommended by oncologists for both early-stage and advanced hormone-sensitive breast cancer. It is often prescribed after surgery, radiation therapy, or chemotherapy to support long-term disease control and improve treatment outcomes.
ANALIEVA 1 MG is commonly prescribed for:
• Hormone Receptor-Positive Breast Cancer
• Early-Stage Breast Cancer
• Advanced Breast Cancer
• Metastatic Breast Cancer
• Adjuvant Hormonal Therapy
• Long-Term Breast Cancer Management
• Postmenopausal Breast Cancer Treatment
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, efficacy, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and hormonal cancer therapy.
Patients receiving ANALIEVA 1 MG may require regular medical monitoring, bone density assessments, cholesterol evaluations, and routine follow-up visits to ensure treatment effectiveness and manage potential side effects.
Due to its proven effectiveness in reducing breast cancer recurrence and supporting long-term disease management, ANALIEVA 1 MG remains an essential medicine in modern breast cancer care.
View Details
Palbociclib Capsules 125mg
PALBOLIEVA 125 MG (Palbociclib Capsules 125 mg) is a prescription targeted anticancer medicine containing Palbociclib 125 mg, an advanced CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used primarily for the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed as part of combination therapy with hormonal treatments to help slow cancer growth and improve treatment outcomes.
Breast cancer is one of the most common cancers affecting women worldwide. Certain breast cancers depend on hormones such as estrogen and progesterone for growth. In these cancers, abnormal cell cycle activity can cause uncontrolled tumor growth and disease progression. PALBOLIEVA 125 MG works by targeting proteins known as CDK4 and CDK6, which play a critical role in cell division and cancer cell proliferation.
By blocking these proteins, Palbociclib helps stop cancer cells from progressing through the cell cycle, thereby slowing tumor growth and delaying disease progression. This targeted mechanism has transformed the treatment landscape for HR-positive, HER2-negative advanced breast cancer and has become a standard component of modern oncology care.
Unlike conventional chemotherapy, Palbociclib specifically targets cancer growth pathways while working alongside hormone therapies such as aromatase inhibitors or fulvestrant. This precision-based approach allows for more effective disease control while helping maintain quality of life.
PALBOLIEVA 125 MG is commonly prescribed for:
HR-Positive, HER2-Negative Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Recurrent Breast Cancer
Hormone Receptor-Positive Breast Cancer
Combination Endocrine Therapy Programs
Targeted Oncology Treatment Plans
Long-Term Breast Cancer Management
The medicine is typically prescribed after careful evaluation by an oncologist and may be used in different stages of advanced breast cancer treatment depending on the patient's medical condition and treatment history.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 125 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function tests, infection assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 125 MG has become an important treatment option in modern breast cancer management worldwide.
View Details
Palbolieva Capsules 100mg
PALBOLIEVA 100 MG (Palbociclib Capsules 100 mg) is a prescription targeted anticancer medicine containing Palbociclib 100 mg, a highly effective CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used in the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed in combination with hormone therapies to help slow cancer progression, control tumor growth, and improve patient outcomes.
Breast cancer remains one of the most frequently diagnosed cancers worldwide. Many breast cancer cells rely on hormones such as estrogen for growth and survival. In HR-positive breast cancer, abnormal activation of cellular pathways can cause uncontrolled cell division and tumor progression. PALBOLIEVA 100 MG is specifically designed to target these pathways by blocking CDK4 and CDK6 proteins, which are essential for cancer cell multiplication.
By preventing cancer cells from progressing through critical stages of the cell cycle, Palbociclib helps reduce tumor growth and delay disease progression. This targeted mechanism has significantly improved treatment strategies for patients with advanced and metastatic hormone receptor-positive breast cancer.
Unlike traditional chemotherapy, which affects rapidly dividing healthy and cancerous cells alike, Palbociclib offers a more precise approach by targeting specific proteins involved in cancer cell proliferation. This allows it to work effectively alongside endocrine therapies such as aromatase inhibitors and fulvestrant.
PALBOLIEVA 100 MG is commonly prescribed for:
HR-Positive, HER2-Negative Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Recurrent Breast Cancer
Hormone Receptor-Positive Breast Cancer
Combination Endocrine Therapy Programs
Targeted Oncology Treatment Plans
Long-Term Breast Cancer Management
The medicine is often used as part of personalized treatment strategies developed by oncologists based on the patient’s cancer stage, medical history, and treatment goals.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function assessments, infection evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 100 MG has become an important treatment option in modern breast cancer care worldwide.
View Details
Fulvestrant Injection 250 MG
Falsolieva 250 mg contains Fulvestrant, a hormonal anticancer medicine classified as a Selective Estrogen Receptor Degrader (SERD). It works by binding to estrogen receptors and causing their degradation, thereby blocking estrogen-driven growth of hormone-dependent breast cancer cells.
View Details
